The Pre-treatment Systemic Inflammatory Response Biomarkers are Important Determinant of Prognosis for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer

Hala Zaghloul 1 and Ahmed Abbas 2*
1 Clinical Oncology Department, Faculty of Medicine, Alexandria, University, Egypt
2 Surgery Department, National Cancer Institute, Cairo University, Egypt

Abstract

Purpose: This research looks at inflammatory response biomarkers in the context of their prognostic potential, derived neutrophil to lymphocyte ratio (dNLR), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and lymphocyte to monocyte ratio (LMR) in patients suffering from rectal cancer and being administered neoadjuvant chemoradiation preceding surgical resection.

Methods: This work offers a retrospective review of "T3/T4, or N+ rectal cancer receiving neoadjuvant chemoradiation 50.4 Gy concurrently with either 5 FU (1 g/m2/d) or Capecitabine 825 mg/m2 twice daily. Pretreatment NLR, dNLR, PLR and LMR measured with the help of peripheral blood cell counts were correlated to clinicopathological parameters. Baseline NLR, dNLR, PLR and LMR prognostic value for disease free survival (DFS) and overall survival (OS) were studied through Cox regression and Log rank.

Results: This study revolved around 80 participants who had undergone resection subsequent to neoadjuvant chemoradiation. ROC or receiver operating curve cut off values for baseline were NLR (3), dNLR (2.1), LMR (4.9) and PLR(169). Augmented NLR, dNLR, PLR, LMR , age ≥50 years , depth of invasion ≥T3 , lymph node N1-N2, stage III , grade 3 tumors, and partial response to pre-operative chemo-radiation were significantly correlated to reduced OS and DFS. A multivariate evaluation highlighted that risen NLR and dNLR stood as independent elements for worsened OS with an HR (hazard ratio) of 2.34 (95% CI= 3.41-7.24), 4.53 (95% CI, 2.61-8.32) and poor DSF with HR 1.64 (95% CI= 2.27-5.36), 4.23 (95% CI= 3.49-9.52), respectively."

Conclusion: The baseline inflammatory prognosticators revealed substantial link to various prognostic clinicopathological parameters in the context of rectal cancer patients who had undergone neoadjuvant chemo-radiation. Moreover, both NLR and dNLR can be seen as possible independent indicators for prognosis in the given patient group.

Keywords: Pre-treatment; Systemic inflammatory response; Biomarkers; Prognostic potential in Rectal Cancer; Chemoradiation

Introduction

The fundamental curative treatment of rectal cancers which comprised one third of the whole colorectal cancer pool, is surgery that entailed total mesorectal excision [1,2]. Neoadjuvant chemo-radiotherapy is the authorized adjunctive modality in mesorectal fascia boundary-mening of rectal cancer. This method considerably ameliorated purging circumambient resection-sidelines consequently substantially minimizing risk of confined relapse [3-6]. The conventionally practiced extrapolative approaches based on presenting tumor burden were proved to be extremely restrictive in forecasting the outcome due to incongruity of prognosis in patients that were categorized to belong to the same clinical disease stage[7-9]. Additionally, the tremendous inconsistence in response to preoperative chemo-radiation (nCRT) amplified the necessity to explore innovative prognosticators that can accurately anticipate the destiny of rectal cancer patients. Lately, several peripheral blood indicators such as the neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), platelet to lymphocyte ratio (PLR) and lymphocyte to monocyte ratio (LMR) have been authorized as extrapolative indicators in various kinds of cancers [12,13]. An amplified NLR was linked to abysmal consequences in colorectal cancer [14]. Meanwhile, PLR was perceived to be unreliable as a prognosticator based on its contradictory impact of outcomes as reported by the available body of evidence [15-18]. Nevertheless, antecedent researches scrutinized on the interaction of a maximum two of inflammatory cells driven prognosticators with outcomes[19-21]. Further to this, the optimal cut-offs for the designated indicators were encountered in studies that weren’t consistent with regards to their prognostic potentials. Accordingly, supplementary authentication of the extrapolative modulation exerted by inflammatory prognosticators on clinical consequences is indispensable. Hence our conducted work delved into the collaboration of NLR, PLR, dNLR and LMR with various clinical-pathological variables alongside their survival modulation to forecast the outcome of rectal cancer patients managed with preoperative chemo-radiation.

Material and Methods

Records of rectal cancer patients managed Clinical Oncology Alexandria University and Surgical Oncology department and National Cancer Institute Cairo University between January 2012 and December 2016, were reviewed to segregate eligible participants.

*Corresponding author: Dr. Hala Ahmed Zaghloul Isamii El Lathy, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Alexandria University, Egypt. Tel: 00201223926059; Fax: 00203429074; E-mail: h_zaghloul@yahoo.com

Received April 29, 2017; Accepted May 22, 2017; Published May 26, 2017

Citation: Zaghloul H, Abbas A (2017) The Pre-treatment Systemic Inflammatory Response Biomarkers are Important Determinant of Prognosis for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer. J Cancer Sci Ther 9: 451-458. doi: 10.4172/1948-5956.1000458

Copyright: © 2017 Zaghloul H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The process was initiated after approvals were acquired from the Institutional Board Approval (IRB). The participants agreed to the study through informed consent, which they signed for. The records were reviewed to gather all clinical-pathological date of the rectal cancer patients managed with preoperative chemo-radiation. All laboratory work ups were revised to record the designated scores of pretreatment differential blood cells in addition to platelet counts. The extraprolitative indicators neutrophil count to lymphocyte count (NLR), derived neutrophil to lymphocyte ratio (dNLR) was constructed as follows: dNLR= neutrophil count to (white cell count-neutrophil count), platelet to lymphocyte ratio (PLR) and lymphocyte to monocyte ratio (LMR) were calculated.

We selectively included pathologically confirmed clinically staged T3/T4 and/or node positive rectal cancers. All participants the course of preoperative chemo-radiation that entailed 50.4 Gy in 1.8 Gy fractions as whole pelvic radiation with concomitant 5-Fluorouracil (1 g/m2/d) as sustained 120 hours infusion during first and fifth weeks of radiation, or 5-Fluorouracil (400 mg/m2/d) and leucovorin 20 mg/m2 intravenous bolus for 4 days during the first and fifth weeks of radiation. Alternatively, Capecitabine 825 mg/m2 twice daily five days per week concurrent with radiation. Total mesorectal excision (TME) surgery was performed 4–6 weeks after conclusion of preoperative CRT. Four additional cycles of 5-FU chemotherapy (500 mg/m2/d, i.v. bolus) or capecitabine (2500 mg/m2 days 1-14, repeated day 22), were applied postoperatively."

Assessment of Response to nCRT

RECIST criteria 1.1. was used to check radiologic response to therapy. It was outlined to be both primary tumor and lymph nodes downsizing as per pre and post neoadjuvant treatment MRI [22]. Total mesorectal excision (TME) was performed in all patients, however extent of surgery whether low anterior or abdomino-perineal resection was based on the initial tumor location. Surgery were performed 4–6 weeks after completion of neoadjuvant CRT. Only patients with R0 resection were included. R0 resection was defined as removal of all gross tumor and histopathologic examination of proximal, distal, and circumferential margins that revealed the absence of malignant cells more than 2 mm from the edge. On the contrary, we exempted patients who suffered from disseminated disease and those who had microscopic (R1) or macroscopic(R2) remaining disease postoperatively."

Follow up periods including (clinical exam, lab tests, imaging and endoscopy), stood between the 3 to 50 months and were arranged at 4-6 months interval.

Statistical Consideration

To inaugurate the extent of influence among intersected clinical-pathological variables including the verified prognosticators either Mann-Whitney U test (between 2 groups) or Kruskal- Wallis test (≥3 groups) were conducted. The receiver operator curves were devised to uncover the optimal thresholds of studied indicators in anticipating survival times. An area under the curve (AUC) of 1.0 would implied a significant test.

"Statistical informative levels stood at P<0.05. Log-rank test and Cox regression analysis were executed to associate clinical and pathological parameters to treatment outcomes. All analyses were performed using SPSS 16.0 package program, (SPSS, Chicago, IL)."

Results

The retrospective review of rectal cancer resulted in eighty patients managed with preoperative chemo-radiation followed by R0-TME with 54 (67.5%) men and 26 (32.5%) women while the median age stood at 52 years. The median values of baseline NLR, dNLR, LMR and PLR were 3.8, 3, 4.2 and 156 respectively. All baseline facets can be reviewed in (Table 1). The NLR, dNLR optimal thresholds 3 (AUC:0.778) and 2.1(AUC:0.740) efficiently forecasted DFS with sensitivity (78.7%,77.3%) and specificity (85.3%,84.3%), respectively. In the same vein, LMR and PLR optimal cutoffs 4.9(AUC: 0.612) and169 (AUC: 0.545) recoded a sensitivity (68.7%,68.3%) and specificity (76.5%,68.3%), correspondingly (Figure 1). Patients were subsequently allocated into two clusters centered on the optimal cut-off levels.

Different clinical-pathological elements were linked with the tested prognosticators. Correspondingly, the stage III denoting larger tumor sizes and more extensive infiltration of draining nodes were strongly interconnected to augmented scores of NLR, dNLR, LMR and PLR compared to lesser tumor burden tumors (Table 2)."

It is worth mentioning, that processing of postoperative specimens confirmed total disappearance of malignant cells from primary tumor bed and regional nodes (path CR) in 12.5% or 10 patients, whereas remaining malignant cells (path PR) were retrieved in (80%) or 64 participants. Therefore, the global response percentage stood at 92.5% i.e. 74 patients, whereas the leftover 6 patients, who accounted for 7.5%, demonstrated progressive or stable disease after preoperative chemo-radiation. All details of down staging were displayed in (Table 3). The median number of nodes examined in the 80 TME specimens was 16 (range, 6 to 22 nodes). The median number of nodes with carcinoma was 4, and the median number of cancer-free nodes was 12."

Several factors were ensuring pathological complete response as Tstage baseline, N stage baseline, and histopathological grade. The superior response was interconnected with lesser stage (P=0.002) and reduced baseline prognosticators NLR (P=0.001), d NLR(P=0.002), LMR (P<0.001) and PLR(P<0.003), respectively(Table 4).

During follow up period, 12.5% or 26 patients were found to have distant metastasis or local recurrence. From this pool, 27.5% or 22 died from cancer-related complications. The OS and DFS median stood at 28 and 24 months, in that order. Further, the three-year overall survival stood at 72.5% while the disease-free survival registered at 67.5% (Figures 2 and 3). The detailed analysis of survival established that advanced stage, partial response to preoperative chemo-radiation (Figures 4 and 5) and augmented NLR (≥3), (Figures 6 and 7), dNLR (≥2.1) (Figures 8 and 9), PLR (≥169), LMR (≥4.9) exhibited a strong link to worsened OS, and DFS (Table 5).

Multivariate scrutiny demonstrated that a accentuated baseline NLR and dNLR alongside advanced TNM stage at diagnosis were individually linked with abysmal OS, with hazard ratio 2.34 (95% confidence interval [CI], 3.41-7.24), 4.53 (95% CI, 2.61-8.32) and 4.21 (95% CI, 2.24-9.73), respectively. Similarly, worsened disease-free survival was profoundly attributed to augmented NLR, dNLR along with advanced TNM stage at diagnosis independently, with hazard ratio 1.64 (95% [CI], 2.27-5.36), 2.63 (95% CI, 2.61-8.12), 6.21 (95% CI, 1.28-14.23), respectively."

Discussion

The mediators instigated in tumor microenvironment through interaction with host native immune system orchestrates the chains of conditioning and sensitizing interaction of inflammatory cells both in tumor milieu and systemically in peripheral blood that reflect the proliferation of carcinogenesis. For instance, NLR, d-NLR, PLR and
LMR that represented systematic indicators of inflammatory reactions induced by colorectal (CRC)malignancies in addition they operated as forecasters of outcome in CRC patients [23, 24]. Consequently, the current work fundamental target was to emphasize the influence of baseline NLR, dNLR, LMR and PLR prognosticators in conjecturing the prognosis of rectal cancer patients undergoing preoperative chemo-radiation. The baseline NLR, dNLR, LMR and PLR forecasted DFS with informative areas under the curve (AUC) of 0.778, 0.740, 0.612 and 0.545 respectively. Similarly, Ying et al reported that preoperative NLR, d-NLR, PLR are robust prognosticators for colorectal cancer patients with ROC (AUC) of 0.764, 0.672, 0.727 respectively. However, baseline LMR was exempted due to its non-significant AUC of 0.234 [25]. The discordance about the influence of baseline LMR can be principally attributed to the structure of studied population as we encompassed exclusively rectal cancer patients, while Ying et al enrolled both colon and rectal cancer patients in their analysis. Moreover, larger tumor burdens were strongly interconnected to augmented scores of NLR, dNLR, LMR and PLR compared to lesser tumor encumbrance. Ying et reached a resembling conclusion that accentuated baseline prognosticators were strongly attributed to advanced disease [25].

As far as the authors of this study know, this is the first of its kind to successfully isolate cut off values for baseline biomarkers. "More importantly, superior responses were interconnected with lesser stage (P=0.002) and reduced baseline prognosticators NLR (P=0.001), dNLR, PLR and LMR compared to augmented scores of NLR, dNLR, LMR and PLR. It is imperative to mention that the results indicated advanced stage, partial response to preoperative chemo-radiation and augmented NLR (≥3), dNLR (≥2.1), PLR (≥169), LMR (≥4.9) exhibited a strong link to worsened OS, and DFS. On the other hand, multiple regression analysis showed that augmented baseline NLR, dNLR along with advanced TNM stage at diagnosis had independent correlation to shortened OS and DFS." In the same vein, Ying et al reported that elevated NLR, poorly differentiated tumors and larger tumor burdens stage were strongly interconnected with compromised OS and DFS [25]. The concordance established between the consequences of the current study and the prosperous body of evidence, emphasized on the forecasting influence of baseline prognosticators NLR, dNLR in rectal cancer patients curatively treated with preoperative chemo-radiation.

**Table 1:** Patient characteristics at baseline (N=80).

| Characteristic | No. of Patients | %   |
|----------------|-----------------|-----|
| Age, years     |                 |     |
| Median         | 52              |     |
| <50            | 38              | 45% |
| ≥50            | 44              | 55% |
| Sex            |                 |     |
| Male           | 54              | 67.5%|
| Female         | 26              | 32.5%|
| Zubrod performance scale |       |     |
| 0              | 36              | 45% |
| 1              | 38              | 47.5%|
| 2              | 6               | 7.5% |
| Histopathological type |       |     |
| Well differentiated | 6            | 7.5%  |
| Moderately differentiated | 56        | 70%  |
| Poorly differentiated | 5           | 6.3%  |
| Mucinous       | 7               | 8.7% |
| Signet Ring    | 6               | 7.5% |
| T stage        |                 |     |
| T1             | 12              | 11.5%|
| T2             | 18              | 22.5%|
| T3             | 44              | 55%  |
| T4a,b          | 6               | 7.5% |
| N stage        |                 |     |
| N0             | 18              | 22.5%|
| N1             | 48              | 60%  |
| N2             | 14              | 17.5%|
| Stage group    |                 |     |
| IIA            | 8               | 10%  |
| IB, C          | 10              | 12.5%|
| III (Any T N1, N2) | 62       | 77.5%|
| Vascular invasion |           |     |
| No vascular invasion | 48         | 60%  |
| Vascular invasion | 32           | 40%  |
| Inflammatory response biomarkers |       |     |
| NLR            |                 |     |
| Median         | 3.8             |     |
| < 3            | 54              | 67.5%|
| ≥ 3            | 26              | 32.5%|
| dNLR           |                 |     |
| Median         | 3               |     |
| < 2.1          | 48              | 60%  |
| ≥ 2.1          | 32              | 40%  |
| LMR            |                 |     |
| Median         | 4.2             |     |
| < 4.9          | 49              | 61.2%|
| ≥ 4.9          | 31              | 38.8%|
| LMR            |                 |     |
| Median         | 156             |     |
| < 169          | 47              | 58.7%|
| ≥ 169          | 33              | 41.3%|
| Surgical procedure |           |     |
| Anterior resection | 56        | 70%  |
| Abdominoperineal resection | 24   | 30%  |
| Radiological response |       |     |
| Complete response unknown | 10 | 12.5% |
| Partial response ≥30% | 33 | 41.3% |
| Stable disease | 22              | 27.5%|
| Progressive disease | 15         | 18.7%|

Figure 1: The receiver operator curve (ROC) of baseline NLR, dNLR, LMR, PLR in rectal cancer patients.
The interaction of neutrophils with distinct malignant cell populations can be provoked by interleukin-6, tumor necrosis factor alpha and granulocyte colony-stimulating factor, myeloid growth factors. It subsequently stimulated an army of cytokines and effector molecules, such as circulating vascular endothelial growth factor (VEGF) which enhanced tumor angiogenesis, growth and metastasis [31-37]. Moreover, the tumor induced neutrophils amplification can suppress native cellular immunity by suppressing tumoricidal activity of cytotoxic CD8+ T cells and accentuating T regulatory cells resulting in tumor proliferation [38,39].

The eloquence of the current work resides essentially on emphasizing the role of NLR, dNLR, PLR and LMR as potent prognosticators in rectal cancer managed with preoperative chemo-radiation. Moreover, the forecasting potential of the tested prognosticators was confirmed in a homogeneous population receiving consistent preoperative and surgical procedures. However, the retrospective scheme and limited number of participants were major contenders for absolute validation of our results and they necessitated further verification in a properly designed randomized trial.

Conclusion

The baseline inflammatory forecasters revealed substantial link to various prognostic clinic-pathological parameters in the context of rectal cancer patients who had undergone neoadjuvant chemoradiation. Moreover, both NLR and dNLR can be seen as possible independent predictors for prognosis in the given patient group.

Conflict of Interest

The authors confirm that no funding or finances were acquired or received from the institutes that they share an affiliation with. The same is true for any external entities, including companies. Furthermore, the authors confirm that they had no conflict of interest to report in the context of this study.

References

1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66: 7-30.
2. Powell AG, Wallace R, McKee RF, Anderson J, Going JJ, et al. (2012) The relationship between tumour site, clinicopathological characteristics, and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Dis 14: 1493-1499.
Table 4: Association between pathological response and different clinicopathological parameters.

| Characteristic                  | Patients | Complete pathologic response, Total=10 Pts | P Value | Partial pathologic response, Total=64 pts | P value |
|-------------------------------|----------|---------------------------------------------|---------|-------------------------------------------|---------|
|                               |          | No | %CR |                                   | No | %PR |
| Age, years                    |          |    |     |                                   |    |     |
| < 50                          | 36       | 5  | 50% | 0.74                                | 30 | 46.8% | 0.91 |
| ≥50                           | 44       | 5  | 50% |                                   | 34 | 53.2% |
| Sex                           |          |    |     |                                   |    |     |
| Male                          | 54       | 5  | 50% | 0.82                                | 43 | 67.2% | 0.88 |
| Female                        | 26       | 5  | 50% |                                   | 21 | 32.8% |
| Histopathological type        |          |    |     |                                   |    |     |
| Well differentiated           | 6        | 4  | 40% | 0.03*                               | 2  | 3.1%  |
| Moderately differentiated     | 56       | 6  | 60% |                                   | 50 | 78.1% | 0.02* |
| Poorly differentiated         | 5        | 0  | 0%  |                                   | 4  | 6.3%  |
| Mucinous                      | 7        | 0  | 0%  |                                   | 6  | 9.3%  |
| Signet Ring                   | 6        | 0  | 0%  |                                   | 2  | 3.1%  |
| T stage                       |          |    |     |                                   |    |     |
| T1                            | 12       | 2  | 20% | 0.002*                              | 10 | 15.6% | 0.001* |
| T2                            | 18       | 2  | 20% |                                   | 16 | 25%   | 0.001* |
| T3                            | 44       | 6  | 60% |                                   | 38 | 59.4% |
| T4 a, b                       | 6        | 0  | 0%  |                                   |    |       |
| N stage                       |          |    |     |                                   |    |     |
| N0                            | 18       | 8  | 80% | 0.001 *                             | 10 | 15.6% | 0.003* |
| N1                            | 48       | 2  | 20% |                                   | 46 | 71.9% |
| N2                            | 14       | 0  | 0%  |                                   | 8  | 12.5% |
| Stage group                   |          |    |     |                                   |    |     |
| IIA                           | 8        | 6  | 60% |                                   | 2  | 3.1%  |
| IIB, C                        | 10       | 0  | 0%  | 0.01*                               | 10 | 15.6% | 0.03* |
| III (Any T N1, N2)            | 62       | 4  | 40% |                                   | 52 | 81.3% |
| Vascular invasion             |          |    |     |                                   |    |     |
| No vascular invasion          | 48       | 8  | 80% | 0.001 *                             | 46 | 71.9% | 0.002* |
| Vascular invasion             | 32       | 2  | 2%  |                                   | 18 | 28.1% |
| Inflammatory response biomarkers|      |   |    |                                   |    |     |
| NLR                           |          |    |     |                                   |    |     |
| Median                        | 3.8      |    |     |                                   |    |     |
| < 3                           | 54       | 9  | 90% | 0.001*                              | 45 | 70.3% | 0.003* |
| ≥ 3                           | 26       | 1  | 10% |                                   | 19 | 29.6% |
| dNLR                          |          |    |     |                                   |    |     |
| Median                        | 3        |    |     |                                   |    |     |
| < 2.1                         | 48       | 8  | 80% | 0.002*                              | 40 | 62.5% |
| ≥ 2.1                         | 32       | 2  | 20% |                                   | 24 | 37.5% |
| LMR                           |          |    |     |                                   |    |     |
| Median                        | 4.2      |    |     |                                   |    |     |
| < 4.9                         | 49       | 7  | 70% | 0.001*                              | 42 | 65.6% | 0.04* |
| ≥ 4.9                         | 31       | 3  | 30% |                                   | 22 | 34.4% |
| PLR                           |          |    |     |                                   |    |     |
| Median                        | 159      |    |     |                                   |    |     |
| < 169                         | 47       | 6  | 60% | 0.003*                              | 41 | 64%   | 0.001* |
| ≥ 169                         | 33       | 4  | 40% |                                   | 23 | 36%   |

3. Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, et al. (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27: 5124-5130.

4. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, et al. (2004) Preoperative versus post-operative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740.

5. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, et al. (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 373: 811-920.

6. Quirke P (2003) Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol 4: 695-702.

7. Hari DM, Leung AM, Lee JH (2013) AJCC cancer staging manual 7th edition criteria for colon cancer: Do the complex modifications improve prognostic assessment? J Am Coll Surg 217: 181-190.

8. Trakarnsanga A, Gonen M, Shia J (2014) Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J Natl Cancer Inst 106: 248.

9. Benson AB3rd, Schrag D, Somerfield MR (2004) American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408-3419.

10. Templeton AJ, McNamara MG, Seruga B (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106: 124.
Figure 2: Overall Survival in months in rectal cancer patients treated with neoadjuvant chemoradiation.

Figure 3: Disease free Survival in months in rectal cancer patients treated with neoadjuvant chemoradiation.

Figure 4: Overall survival by pathological response in months.

Figure 5: Disease free survival by pathological response in months.

Figure 6: Overall survival by NLR cutoff level in months.

Figure 7: Disease free survival by NLR cutoff level in months.
and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer.

18. Ying HQ, Deng QW, He BS (2014) The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol (Northwood, London, England) 31: 305.

19. Neofytou K, Smyth EC, Giakoustidis A (2014) Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol (Northwood, London, England) 31: 239.

20. Kwon HC, Kim SH, Oh SY (2012) Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17: 216.

21. Son HU, Park JW, Chang HJ (2013) Preoperative plasma hyper fibrinogenemia is predictive of poor prognosis in patients with non-metastatic colon cancer. Ann Surg Oncol 20: 2908-2913.

22. Eisenhauer EA, Therasse P, Bogaerts J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45: 228-247.

23. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.

24. Cedre’s S, Torreon D, Martínez A, Martinez P, Navarro A, et al. (2012) Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 14: 864-869.

25. Ying HQ, Deng QW, He BS (2014) The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol 2014 31: 305.

26. Cedre’s S, Torreon D, Martínez A, Martinez P, Navarro A, et al. (2012) Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 14: 864-869.

27. Stotz M, Gerger A, Elsner F, Szakandera J, Lohbner H, et al. (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109: 416-421.

28. Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, et al. (2013) Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: A retrospective analysis. Ann Surg 258: 301-305.

29. Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, et al. (2013) Significance of preoperative neutrophil-to-lymphocyte ratio as a predictor of prognosis in patients with stage IV colorectal cancer. Gan To Kagaku Ryoho 40: 1603-1605.

30. Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, et al. (2013) A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer, Anticancer Res 33: 3291-3294.

31. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6: 283-287.

32. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 208: 183194.

33. Kim SL, Lee ST, Trang KT, Kim SH, Kim IH, et al. (2014) Parthenolide exerts inhibitory effects on angiogenesis through the down regulation of VEGF/VEGFRs in colorectal cancer. J Mol Med 33: 1261-1267.

34. Kuper H, Adami HO, Triopoulos D (2000) Infections as a major preventable cause of human cancer. J Intern Med 248: 171-183.

35. Blaser MJ, Chyov PH, Nomura A (1995) Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 55: 562-565.

36. Scholl SM, Paucl C, Beuvon F, Hacene K, Stanley ER, et al. (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86: 120-126.
### Table 5: Association between different clinicopathological parameters and clinical prognosis.

| Characteristic                                      | No. of Patients and % | Overall survival No (%) of patients alive 58 | Disease free survival No (%) of patients 52 free of disease | P value |
|-----------------------------------------------------|-----------------------|-----------------------------------------------|-------------------------------------------------------------|---------|
| Age, years                                          |                       |                                               |                                                             |         |
| <50                                                 | 38 (45%)              | 26 (44.8%)                                    | 22 (42.3%)                                                 | 0.01*   |
| ≥50                                                 | 44 (55%)              | 32 (55.2%)                                    | 30 (57.7%)                                                 | 0.012*  |
| Sex                                                 |                       |                                               |                                                             |         |
| Male                                                | 54 (67.5%)            | 28 (48.3%)                                    | 27 (51.9%)                                                 | 0.534   |
| Female                                              | 26 (32.5%)            | 30 (51.7%)                                    | 25 (48.1%)                                                 |         |
| Histopathological type at diagnosis                 |                       |                                               |                                                             |         |
| Well differentiated                                  | 6 (7.5%)              | 6 (10.3%)                                     | 6 (11.5%)                                                  | 0.002*  |
| Moderately differentiated                           | 56 (70%)              | 48 (84.5%)                                    | 44 (84.6%)                                                 | 0.011*  |
| Poorly differentiated                               | 5 (6.3%)              | 1 (1.7%)                                      | 1 (1.9%)                                                   |         |
| Micinous                                            | 7 (8.7%)              | 1 (1.7%)                                      | 1 (1.9%)                                                   |         |
| Signet Ring                                         | 6 (7.5%)              | 1                                              | 1                                                          |         |
| T stage at diagnosis                                |                       |                                               |                                                             |         |
| T1                                                  | 12 (11.5%)            | 12 (20.6%)                                    | 12 (23.1%)                                                 | 0.003*  |
| T2                                                  | 18 (22.5%)            | 18 (31%)                                      | 17 (32.7%)                                                 | 0.012*  |
| T3                                                  | 44 (55%)              | 31 (53.4%)                                    | 23 (44.2%)                                                 | 0.004*  |
| T4                                                  | 6 (7.5%)              | 1 (1.7%)                                      | 0                                                          |         |
| N stage at diagnosis                                |                       |                                               |                                                             |         |
| N0                                                  | 18 (22.5%)            | 18 (31%)                                      | 18 (34.6%)                                                 | 0.031*  |
| N1                                                  | 48 (60%)              | 36 (62%)                                      | 32 (61.5%)                                                 |         |
| N2                                                  | 14 (17.5%)            | 4 (7%)                                        | 2 (3.9%)                                                   |         |
| Stage group at diagnosis                            |                       |                                               |                                                             |         |
| IA                                                  | 8 (10%)               | 8 (13.8%)                                     | 8 (15.4%)                                                  | 0.04*   |
| II, B, C                                           | 10 (12.5%)            | 1 (1.7%)                                      | 0                                                          |         |
| III (Any T N1, N2)                                 | 62 (77.5%)            | 49 (84.5%)                                    | 44 (84.6%)                                                 |         |
| Pathological response                               |                       |                                               |                                                             |         |
| Complete response at primary site and LN            | 10 (12.5%)            | 10 (17.2%)                                    | 10 (19.2%)                                                 | 0.003*  |
| Partial response                                    | 64 (80%)              | 46 (79.3%)                                    | 42 (80.8%)                                                 |         |
| Stable or progressive disease                       | 6 (7.5%)              | 2 (3.5%)                                      | 0                                                          |         |
| Inflammatory response biomarkers at diagnosis       |                       |                                               |                                                             |         |
| NLR                                                 |                       |                                               |                                                             |         |
| Median                                              | 3.8                   |                                               |                                                             |         |
| < 3                                                 | 44 (55%)              | 42 (72.4%)                                    | 40 (77%)                                                   | 0.013*  |
| ≥ 3                                                 | 36 (45%)              | 16 (27.6%)                                    | 12 (23%)                                                   | 0.032*  |
| dNLR                                                |                       |                                               |                                                             |         |
| Median                                              | 3                     |                                               |                                                             |         |
| < 2.1                                               | 48 (60%)              | 45 (77.6%)                                    | 41 (79%)                                                   | 0.016*  |
| ≥ 2.1                                               | 32 (40%)              | 13 (22.4%)                                    | 11 (21 %)                                                  | 0.011*  |
| LMR                                                 |                       |                                               |                                                             |         |
| Median                                              | 4.2                   |                                               |                                                             |         |
| < 4.9                                               | 49 (61.2%)            | 46 (79.3%)                                    | 42 (80.8%)                                                 | 0.014*  |
| ≥ 4.9                                               | 31 (38.8%)            | 12 (20.7%)                                    | 10 (19.2%)                                                 | 0.021*  |
| PLR                                                 |                       |                                               |                                                             |         |
| Median                                              | 156                   |                                               |                                                             |         |
| < 169                                               | 47 (58.7%)            | 41 (70.7%)                                    | 39 (75%)                                                   | 0.027*  |
| ≥ 169                                               | 33 (41.3%)            | 17 (29.3%)                                    | 13 (25%)                                                   | 0.001*  |

37. Shacter E, Weitzman SA (2002) Chronic inflammation and cancer Oncology 16: 217-226.

38. Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A (1987) Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173-177.

39. Menges T, Engel J, Welters I, Wagner RM, Little S, et al. (1999) Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med 27: 733-740.